Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Ono Pharmaceutical Co., Ltd.
  6. Summary
    4528   JP3197600004

ONO PHARMACEUTICAL CO., LTD.

(4528)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
2796(c) 2774(c) 2704(c) 2716.5(c) 2700.5(c) Last
1 372 200 1 037 200 1 334 600 1 272 000 1 379 600 Volume
-1.04% -0.79% -2.52% +0.46% -0.59% Change
More quotes
Estimated financial data (e)
Sales 2022 359 B 3 152 M 3 152 M
Net income 2022 85 057 M 748 M 748 M
Net cash position 2022 90 053 M 792 M 792 M
P/E ratio 2022 15,8x
Yield 2022 2,05%
Sales 2023 411 B 3 612 M 3 612 M
Net income 2023 107 B 942 M 942 M
Net cash position 2023 135 B 1 184 M 1 184 M
P/E ratio 2023 12,5x
Yield 2023 2,44%
Capitalization 1 333 B 11 711 M 11 717 M
EV / Sales 2022 3,47x
EV / Sales 2023 2,92x
Nbr of Employees 3 607
Free-Float -
More Financials
Company
ONO PHARMACEUTICAL CO., LTD. is a Japan-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates in one business segment. The Pharmaceutical segment involves in the manufacture and sale of drugs for medical and general use. The Company also involves in the clinical development, introduction and derivation of pharmaceuticals. 
Sector
Pharmaceuticals
Calendar
01/30 | 10:00pmEarnings Release
More about the company
Ratings of Ono Pharmaceutical Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about ONO PHARMACEUTICAL CO., LTD.
01/17Neurimmune AG Expands Drug Discovery Collaboration with Ono Pharmaceutical in the Field..
CI
01/06Ono Pharmaceutical Co., Ltd. - Opdivo Intravenous Infusion Approved for the Adjuvant Tr..
AQ
01/04Tranche Update on Ono Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on Novem..
CI
2021Ono Extends Drug Discovery Collaboration Agreement with Vanderbilt University
AQ
2021BMG Incorporated announced that it has received ą130 million in funding from Ono Pharma..
CI
2021ONO Pharmaceutical Announces the Foundation of 'ONO Pharmaceutical and Dr. Honjo Honora..
AQ
2021ONO Selected as a Highest Rating A-List Company for Both 'Climate Change' and 'Water Se..
AQ
2021Ono Announces Status of Acquisition of Own Shares
AQ
2021Japanese shares end lower on Omicron worries, Fed's hawkish tilt
RE
2021Japanese shares fall on Omicron, Fed worries
RE
2021R & D - ONO Receives Approval of Opdivo (nivolumab) for Expanded Use for Two Indication..
AQ
2021Ono Pharmaceutical Co., Ltd. announces an Equity Buyback for 11,000,000 shares, represe..
CI
2021Ono Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
2021ONO Announces the Settlement of Litigation Raised by Dr. Honjo
AQ
2021Ono Pharmaceutical Co. - Velexbru Tablet 80 mg, a BTK inhibitor, Approved in South Kore..
AQ
More news
News in other languages on ONO PHARMACEUTICAL CO., LTD.
01/17Neurimmune AG étend sa collaboration en matière de découverte de médicaments avec Ono P..
2021Nuevas compras en la cartera Inversor Asia
2021Nouveaux achats dans le portefeuille Investisseur Asie
2021Takeda, partenaire d'Exelixis, obtient un avis favorable pour le combo Cabometyx au Jap..
2021Ono Pharmaceutical Co., Ltd. fournit des prévisions de bénéfices pour l'année 2021
More news
Chart ONO PHARMACEUTICAL CO., LTD.
Duration : Period :
Ono Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ONO PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 2 700,50 JPY
Average target price 3 243,85 JPY
Spread / Average Target 20,1%
EPS Revisions
Managers and Directors
Gyo Sagara Director, VP & Senior General Manager-Business
Toichi Takino Managing Executive Officer & GM-Research
Yutaka Kato Independent Outside Director
Masao Nomura Independent Outside Director
Shusaku Nagae Independent Outside Director